Inhibitory effect of norcantharidin on non-small cell lung cancer by targeting BCL-2/P53 proteins
10.13200/j.cnki.cjb.004484
- VernacularTitle:去甲斑蝥素靶向调控BCL-2/P53蛋白对非小细胞肺癌的遏制作用
- Author:
DONG Yu
- Publication Type:Journal Article
- Keywords:
Non-small cell lung cancer(NSCLC);
Norcantharidin(NCTD);
BCL2;
P53
- From:
Chinese Journal of Biologicals
2025;38(05):562-568
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the expression of BCL-2 and P53 proteins in non-small cell lung cancer(NSCLC) and theinhibitory effect of norcantharidin(NCTD) on NSCLC by targeting the expression of these two key proteins, so as to provideexperimental evidence for developing new therapeutic strategies for NSCLC.MethodsBioinformatics methods were used toanalyze the expression of BCL-2 and P53 in cancer, especially lung cancer, and their correlation with the survival rates ofpatients. The effects of NCTD on proliferation, apoptosis and the expression of BCL-2 and P53 proteins in NSCLC cells weremeasured by CCK-8, flow cytometry and Western blot, respectively.ResultsBCL-2 and P53 proteins were found to behighly expressed in various tumors, with a more pronounced expression in lung cancer(t = 3. 810, P < 0. 05). The expressionof BCL-2 protein was significantly correlated with the survival rates of lung cancer patients(t = 3. 235, P < 0. 05). Theaffinity of NCTD to BCL-2 protein was significantly higher than that to P53 protein. NCTD inhibited the proliferation ofNSCLC cells, promoted the apoptosis, and significantly reduced the expression of BCL-2 and P53 proteins(t = 3. 25 and3. 45, respectively, each P < 0. 05).ConclusionBCL-2 and P53 play a crucial role in the development of NSCLC, andNCTD can effectively inhibit the expression of these two proteins, thereby inhibiting the proliferation of NSCLC cells. Thisstudy provides an experimental basis for developing new therapeutic strategies for NSCLC, and also lays a foundation forfurther research on NCTD as a potential anti-tumor drug.
